[go: up one dir, main page]

PT4321157T - Nova utilização de uma combinação de um bloqueador dos recetores da angiotensina (arb) com um inibidor da endopeptidase neutra (nepi) - Google Patents

Nova utilização de uma combinação de um bloqueador dos recetores da angiotensina (arb) com um inibidor da endopeptidase neutra (nepi)

Info

Publication number
PT4321157T
PT4321157T PT232021907T PT23202190T PT4321157T PT 4321157 T PT4321157 T PT 4321157T PT 232021907 T PT232021907 T PT 232021907T PT 23202190 T PT23202190 T PT 23202190T PT 4321157 T PT4321157 T PT 4321157T
Authority
PT
Portugal
Prior art keywords
nepi
arb
combination
receptor blocker
new use
Prior art date
Application number
PT232021907T
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT4321157(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT4321157T publication Critical patent/PT4321157T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PT232021907T 2013-08-26 2014-08-26 Nova utilização de uma combinação de um bloqueador dos recetores da angiotensina (arb) com um inibidor da endopeptidase neutra (nepi) PT4321157T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
PT4321157T true PT4321157T (pt) 2025-01-08

Family

ID=51494327

Family Applications (3)

Application Number Title Priority Date Filing Date
PT147617021T PT3038654T (pt) 2013-08-26 2014-08-26 Nova utilização
PT232021907T PT4321157T (pt) 2013-08-26 2014-08-26 Nova utilização de uma combinação de um bloqueador dos recetores da angiotensina (arb) com um inibidor da endopeptidase neutra (nepi)
PT192028546T PT3626270T (pt) 2013-08-26 2014-08-26 Tratamento de doenças cardiovasculares

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT147617021T PT3038654T (pt) 2013-08-26 2014-08-26 Nova utilização

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT192028546T PT3626270T (pt) 2013-08-26 2014-08-26 Tratamento de doenças cardiovasculares

Country Status (16)

Country Link
US (2) US20160213646A1 (pt)
EP (4) EP4512397A3 (pt)
JP (1) JP6097888B2 (pt)
CY (1) CY1122531T1 (pt)
DK (3) DK3038654T3 (pt)
ES (3) ES2968541T3 (pt)
FI (2) FI4321157T3 (pt)
HR (3) HRP20200060T1 (pt)
HU (3) HUE064634T2 (pt)
LT (3) LT4321157T (pt)
PL (3) PL4321157T3 (pt)
PT (3) PT3038654T (pt)
RS (3) RS65037B1 (pt)
SI (3) SI3626270T1 (pt)
SM (1) SMT202500001T1 (pt)
WO (1) WO2015028941A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65037B1 (sr) 2013-08-26 2024-02-29 Novartis Ag Lečenje kardiovaskularnih oboljenja
US10562866B2 (en) * 2015-02-06 2020-02-18 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
EP3302460A1 (en) * 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
ES3036922T3 (en) 2016-02-03 2025-09-25 Novartis Ag New use of a combination of sacubitril and valsartan
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2020039386A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
AU2020348813B2 (en) 2019-09-20 2025-09-11 Shenzhen Salubris Pharmaceuticals Co. Ltd Uses of complex of angiotensin II receptor antagonist metabolite and NEP inhibitor in treating heart failure

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DK0966282T3 (da) * 1997-01-10 2003-09-29 Merck & Co Inc Anvendelse af angiotensin ll antagonister til behandling af symptomatisk hjerteinsufficiens
WO2003059345A1 (en) * 2002-01-17 2003-07-24 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
EP1631556A1 (en) * 2003-05-16 2006-03-08 Novartis AG Pharmaceutical composition comprising valsartan
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
FI3067043T3 (fi) 2007-11-06 2023-03-18 Novartis Ag Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
SI2361085T2 (sl) 2008-11-22 2018-11-30 F. Hoffmann-La Roche Ag Uporaba protitelesa proti vegf v kombinaciji s kemoterapijo za zdravljenje raka dojk
RU2564941C2 (ru) * 2010-08-24 2015-10-10 Новартис Аг Лечение гипертензии и/или предотвращение и лечение сердечной недостаточности у млекопитающего, получающего терапию антикоагулянтами
DK2887961T3 (da) 2012-08-24 2021-07-19 Novartis Ag Nep-inhibitorer til behandling af sygdomme, der er kendetegnet ved atrieforstørrelse eller -remodellering
US20160206597A1 (en) * 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
RS65037B1 (sr) 2013-08-26 2024-02-29 Novartis Ag Lečenje kardiovaskularnih oboljenja

Also Published As

Publication number Publication date
ES2767084T3 (es) 2020-06-16
PL3626270T3 (pl) 2024-04-08
US20160213646A1 (en) 2016-07-28
EP3626270B1 (en) 2023-10-11
JP2016528303A (ja) 2016-09-15
EP4321157A2 (en) 2024-02-14
EP4321157A3 (en) 2024-05-15
EP4512397A3 (en) 2025-05-14
RS66371B1 (sr) 2025-02-28
FI3626270T3 (fi) 2024-01-11
WO2015028941A1 (en) 2015-03-05
FI4321157T3 (fi) 2025-01-20
EP3038654B1 (en) 2019-10-30
EP3626270A1 (en) 2020-03-25
HUE069419T2 (hu) 2025-03-28
HUE064634T2 (hu) 2024-04-28
DK4321157T3 (da) 2024-12-16
PT3626270T (pt) 2024-01-11
HRP20241763T1 (hr) 2025-03-14
RS59816B1 (sr) 2020-02-28
PL4321157T3 (pl) 2025-03-03
EP3038654A1 (en) 2016-07-06
SI3038654T1 (sl) 2020-02-28
ES3001196T3 (es) 2025-03-04
SI4321157T1 (sl) 2025-03-31
SI3626270T1 (sl) 2024-03-29
EP4512397A2 (en) 2025-02-26
DK3038654T3 (da) 2020-02-03
HRP20200060T1 (hr) 2020-04-03
HUE047186T2 (hu) 2020-04-28
EP4321157B1 (en) 2024-10-23
LT3038654T (lt) 2020-01-27
JP6097888B2 (ja) 2017-03-15
LT4321157T (lt) 2025-01-10
DK3626270T3 (da) 2024-01-15
ES2968541T3 (es) 2024-05-10
CY1122531T1 (el) 2021-01-27
HRP20240034T1 (hr) 2024-03-29
PT3038654T (pt) 2020-02-04
SMT202500001T1 (it) 2025-03-12
US20210077461A1 (en) 2021-03-18
RS65037B1 (sr) 2024-02-29
PL3038654T3 (pl) 2020-05-18
LT3626270T (lt) 2024-01-25

Similar Documents

Publication Publication Date Title
LT4321157T (lt) Naujas angiotenzino receptoriaus blokatoriaus (arb) ir neutralios endopeptidazės inhibitoriaus (nepi) derinio panaudojimas
EP2970340A4 (en) BETA-Lactamase INHIBITORS
EP2943204A4 (en) BETA-Lactamase INHIBITORS
EP2948450A4 (en) METALLOENZYMINHIBITORVERBINDUNGEN
PT2970272T (pt) Inibidores de glicosidase
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
PL2984871T3 (pl) Operacja pdcp w celu podwójnego połączenia
ZA201506516B (en) Hdac inhibitors
PL3068685T3 (pl) Przewłoka prowadząca elementu kotwicznego
PT3293176T (pt) Forma cristalina de um inibidor de pde4
GB201317609D0 (en) Inhibitor compounds
AP2015008621A0 (en) Substituted bisphenyl butanoic nep 'neutral endopeptidase' inhibitors
GB201300357D0 (en) Plumbing diverter component
IL240019A0 (en) Estrogen receptor inhibitors
GB201309426D0 (en) Biomarkers
EP3084587A4 (en) Determining image rescale factors
HUE070532T2 (hu) NMDA antagonista prodrugok
GB201308077D0 (en) Biomarkers
GB201313664D0 (en) Bcl-3 inhibitors
PL3014029T3 (pl) Zespół syfonu
IL245386A0 (en) A crystalline beta-lactamase inhibitor
SG11201509142UA (en) Detecting endocrine disrupting compounds
GB201321328D0 (en) Inhibitor compounds
GB201305503D0 (en) Inhibitor
GB201320835D0 (en) HIF inhibitors